The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Effects of Cinnamon Supplementation on Glucose Metabolism in Patients With Pre-diabetes (Cinnamon)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03219411
Recruitment Status : Completed
First Posted : July 17, 2017
Last Update Posted : August 19, 2019
Kyunghee University
Information provided by (Responsible Party):
Joslin Diabetes Center

Brief Summary:
The transition from normal glucose tolerance to overt type 2 diabetes mellitus (T2D) encompasses a variety of glycemic abnormalities that are commonly referred to as 'prediabetes'. While intensive lifestyle interventions are the cornerstone of T2D prevention, developing safe, cost-effective adjunct therapeutic strategies is a clinically relevant goal. Cinnamon supplementation has been shown to improve fasting plasma glucose in patients with T2D. This placebo-controlled, randomized study will determine if cinnamon improves glucose homeostasis in patients with prediabetes over a 12-week period.

Condition or disease Intervention/treatment Phase
Dysglycemia Obesity Dietary Supplement: Cinnamon Other: placebo Phase 2

Detailed Description:

BACKGROUND: The transition from normal glucose tolerance and insulin sensitivity to overt type 2 diabetes (T2D) encompasses a variety of glycemic abnormalities that are commonly referred to as 'prediabetes'. In 2003, 314 million people (8.2% of the adult population) had prediabetes, and this number is projected to increase to 472 million (9.0% of the adult population) by 2025. Approximately 40-50% of individuals with prediabetes have been reported to develop T2D within 10 years.

While intensive lifestyle interventions remain the cornerstone of T2D prevention, targeted pharmacotherapy has been shown to be effective and may be considered in high-risk patients. Several antidiabetic medications prevent or, at least, delay the progression from prediabetes to diabetes, including metformin, α-glucosidase inhibitors or pioglitazone. However, cost, potential adverse effects, and secondary failure in the long-term have often limited the widespread use of these and other newer antidiabetic drugs in patients with prediabetes. For instance 10 to 20% of metformin-treated patients experience gastrointestinal side effects (nausea, vomiting, and diarrhea) leading to its discontinuation, whereas the use pioglitazone is often complicated by weight gain and increased risk of fractures.

In this context, efficacious, cost-effective, and safe adjunct therapeutics for T2D prevention are highly desirable. The present trial proposes to test the effects of cinnamon in patients with prediabetes.

RATIONALE: Several randomized controlled studies have addressed the effects of cinnamon on changes in glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) in adult patients with T2D. Almost all studies showed a significant 10-20% decrease in FPG from baseline and improvements in HbA1c, although the latter change often did not achieve statistical significance. These findings in patients with T2D provide the rational to test whether cinnamon exerts similar beneficial effects in patients with prediabetes.

STUDY DESIGN: This is a multi-center placebo-controlled, randomized (1:1), double masked trail to assess the effects of cinnamon (cinnamomum burmannii) on glucose homeostasis over a 12- week period. FPG, HbA1c, and other measures of glucose metabolism will be collected at baseline, after 6 weeks, and at the end of the 12-week study period. Participants will be prompted to report Adverse Events (AE) at the study visits or anytime during the study period.

OUTCOMES: The primary outcome for the Cinnamon Trial is a change in the FPG level from baseline to week 12 of treatment, as compared to placebo. Secondary outcomes include change in the FPG from baseline to week 6 of treatment, and change from baseline in plasma glucose at 2 hours and area under the curve-glucose during a 75-gram oral glucose tolerance test to week 12. Data will be analyzed using the "intent-to-treat" approach, which includes all randomized subjects with at least one post-baseline FPG measurement; the supplementation group assignment will not be altered based on the subject's adherence to the regimen.

SAMPLE SIZE DETERMINATION: Anticipating an absolute change in FPG smaller than what observed in previous studies in patients with T2D, 10 patients with prediabetes in total entering a two-treatment parallel-design study will provide 90% probability of detecting a true between-treatment difference in FPG means of 22 mg/dl with standard deviation of 10 mg/dl, using a paired two-sided comparison with type 1 error of 0.05. To allow for up to 20% dropout, 12 patients in total will be recruited.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double blind
Primary Purpose: Treatment
Official Title: A Multi-National, Double-Blind, Randomized Trial Of The Influence Of Cinnamon Powders In Subjects With Risk For Developing Diabetes
Actual Study Start Date : August 28, 2017
Actual Primary Completion Date : July 1, 2019
Actual Study Completion Date : July 30, 2019

Arm Intervention/treatment
Active Comparator: Cinnamon
Cinnamon burmannii administered orally as 500-mg capsules three times daily over 12 weeks
Dietary Supplement: Cinnamon
Cinnamon burmannii administered orally as 500-mg capsules three times a day over 12 weeks

Placebo Comparator: Placebo
Placebo administered orally as capsules three times daily over 12 weeks
Other: placebo
Placebo administered orally as capsules three times a day over 12 weeks

Primary Outcome Measures :
  1. Fasting plasma glucose at 12 weeks [ Time Frame: 12 weeks ]
    Change from baseline in fasting plasma glucose at 12 weeks

Secondary Outcome Measures :
  1. Fasting plasma glucose at 6 weeks [ Time Frame: 6 weeks ]
    Change from baseline in fasting plasma glucose at 6 weeks

  2. 2-hour plasma glucose during OGTT (oral glucose tolerance test) [ Time Frame: 12 weeks ]
    Change from baseline in plasma glucose obtained 2 hours during OGTT at 12 weeks

  3. Area under the curve-glucose during OGTT (oral glucose tolerance test) [ Time Frame: 12 weeks ]
    Change from baseline in area under the curve of plasma glucose during OGTT at 12 weeks

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Ages 20 - 70 years old at screening
  2. Meet at least one of the following criteria of Prediabetes according to the 2016 American Diabetes Association criteria:

    1. Impaired Fasting Glucose (IFG [100-125 mg/dL])
    2. Impaired Glucose Tolerance (IGT [2-h plasma glucose: 140-199 mg/dL based on 75-g OGTT])
    3. HbA1c between 5.7-6.4%
  3. Willingness to provide informed consent and follow all study procedures, including attending all scheduled visits.

Exclusion Criteria:

  1. Documented diabetes mellitus diagnosed by a physician and confirmed by other clinical data.
  2. Previous use of any antidiabetic medication.
  3. Cardiovascular disease within 6 months of the study commencement including arrhythmia, congestive heart failure, myocardial infarction or pacemaker placement.
  4. History of uncontrolled hypertension (defined as systolic blood pressure > 150 mmHg or diastolic blood pressure > 95 mmHg on three or more assessments on more than 1 day). If the patient is on blood pressure medications, dosing should be stable for at least 4 weeks prior to randomization.
  5. Cancer diagnosis requiring treatment in the past 5 years
  6. Chronic kidney disease stage 3-5 (estimated glomerular filtration rate < 60; based on MDRD formula or creatinine ≥ 1.4 for men or >1.3 mg/dL for women, or a urine protein ≥ 2+)
  7. Known liver disease or elevation of AST, ALT, or GGT > 2.50 × upper limit of normal at screening.
  8. Other gastrointestinal diseases (including pancreatitis and inflammatory bowel disease)
  9. Participation in other clinical trials within 2 months.
  10. Surgery within 30 days prior to screening.
  11. Pulmonary disease with dependence on oxygen or daily use of bronchodilators.
  12. Chronic infections (e.g., human immune-deficiency virus (HIV) or active tuberculosis)
  13. Allergy or hypersensitivity to any of the ingredients in the test products.
  14. Cognitive impairment or any other reason to expect the patient would have difficulty complying with study protocol
  15. Excessive alcohol intake defined as greater than 3 units of alcohol per day.
  16. Use of weight loss drugs (e.g., lorcaserin [Belviq]; phentermine/topiramate [Qsymia], liraglutide [Saxenda], Xenical [orlistat], Meridia [sibutramine], Acutrim [phenylpropanol-amine], or similar over-the-counter medications) within 3 months of the screening visit.
  17. Intentional weight loss of ≥ 10 lbs in the previous 6 months.
  18. Use of dietary supplements that may have glucose-lowering effects (e.g. Sesame, Polygonatum odoratum, Chromium, Vanadium).
  19. Concurrent enrollment in a weight loss program, such as Weight Watchers.
  20. Other endocrine disorders affecting glucose metabolism including Cushing' syndrome, acromegaly, hyperthyroidism, hypothyroidism or adrenal insufficiency.
  21. Fasting plasma triglyceride >500 mg/dl.
  22. Oral corticosteroids within 3 months.
  23. Pregnancy and/ or Lactation: Women of childbearing potential will be required to have a negative urine pregnancy test and to use contraception measures during the study and for at least 1 month after participating in the study. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant, an IUD, the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence.
  24. Moderate anemia, defined as hemoglobin <10.9 in both men and women based on WHO criteria

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03219411

Layout table for location information
United States, Massachusetts
Joslin Diabetes Center
Boston, Massachusetts, United States, 02215
Sponsors and Collaborators
Joslin Diabetes Center
Kyunghee University
Layout table for investigator information
Principal Investigator: Giulio R Romeo, MD Joslin Diabetes Center
Layout table for additonal information
Responsible Party: Joslin Diabetes Center Identifier: NCT03219411    
Other Study ID Numbers: CHS #:2017-15
First Posted: July 17, 2017    Key Record Dates
Last Update Posted: August 19, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No